Chinese biopharmaceutical firm Kanova has secured RMB115 million (US$16.55 million) series A round of financing from Chinese venture capital firm Northern Light Venture Capital (NLVC), according to a statement released today by NLVC.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?